Premium
Preclinical risk assessment of drug‐induced hypo‐ and hyperprolactinemia
Author(s) -
Hargreaves Adam,
Harleman Johannes
Publication year - 2011
Publication title -
journal of applied toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.784
H-Index - 87
eISSN - 1099-1263
pISSN - 0260-437X
DOI - 10.1002/jat.1723
Subject(s) - drug , medicine , pharmacology , risk assessment , computer science , computer security
ABSTRACT Drug‐induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo‐/hyperprolactinemia can be recognized in short‐ and long‐term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug‐induced hypo‐/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk. Copyright © 2011 John Wiley & Sons, Ltd.